National Research Council Institute for Biological Sciences, Ottawa, Canada.
Int J Med Microbiol. 2011 Nov;301(7):591-601. doi: 10.1016/j.ijmm.2011.07.002. Epub 2011 Aug 27.
Francisella tularensis is pathogenic for many mammalian species including humans, causing a spectrum of diseases called tularemia. The highly virulent Type A strains have associated mortality rates of up to 60% if inhaled. An attenuated live vaccine strain (LVS) is the only vaccine to show efficacy in humans, but suffers several barriers to licensure, including the absence of a correlate of protection. An immunoproteomics approach was used to survey the repertoire of antibodies in sera from individuals who had contracted tularemia during two outbreaks and individuals from two geographical areas who had been vaccinated with NDBR Lot 11 or Lot 17 LVS. These data showed a large overlap in the antibodies generated in response to tularemia infection or LVS vaccination. A total of seven proteins were observed to be reactive with 60% or more sera from vaccinees and convalescents. A further four proteins were recognised by 30-60% of the sera screened. These proteins have the potential to serve as markers of vaccination or candidates for subunit vaccines.
土拉弗朗西斯菌对包括人类在内的许多哺乳动物物种具有致病性，可引起称为土拉菌病的一系列疾病。如果吸入，高度毒力的 A 型菌株的死亡率高达 60%。减毒活疫苗株（LVS）是唯一在人类中显示出疗效的疫苗，但在获得许可方面存在几个障碍，包括缺乏保护相关物。采用免疫蛋白质组学方法调查了在两次暴发期间感染土拉菌病的个体以及用 NDBR Lot 11 或 Lot 17 LVS 接种的来自两个地理区域的个体的血清中的抗体谱。这些数据表明，对土拉菌病感染或 LVS 接种产生的抗体有很大的重叠。共有 7 种蛋白与 60%或更多疫苗接种者和恢复期患者的血清发生反应。另外 4 种蛋白被筛查的 30-60%的血清识别。这些蛋白有可能作为疫苗接种的标志物或亚单位疫苗的候选物。
